(Q36094944)

12 August 2017

In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir (English)

1 reference

12 August 2017

1 reference

3

Tatyana Dekhtyar

1 reference

12 August 2017

11

Akhteruzzaman Molla

1 reference

12 August 2017

8

Dale Kempf

1 reference

12 August 2017

1

Sherie Masse

1 reference

12 August 2017

5

Gennadiy Koev

1 reference

12 August 2017

Xiaozhi Lu

2

1 reference

12 August 2017

Liangjun Lu

4

1 reference

12 August 2017

Feng Gao

6

1 reference

12 August 2017

Hongmei Mo

7

1 reference

12 August 2017

Barry Bernstein

9

1 reference

12 August 2017

George J Hanna

10

1 reference

12 August 2017

language of work or name

English

0 references

publication date

18 June 2007

1 reference

Antimicrobial Agents and Chemotherapy

12 August 2017

1 reference

12 August 2017

51

1 reference

12 August 2017

9

1 reference

12 August 2017

3075-3080

1 reference

Highly active antiretroviral therapy and viral response in HIV type 2 infection

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Molecular cloning and polymorphism of the human immune deficiency virus type 2.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Update of the drug resistance mutations in HIV-1: Fall 2006.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043247

Prevalence of HIV among low and high risk population of eastern part of northern India

23 September 2018

1 reference

12 December 2020

Viral response to antiretroviral therapy in a patient coinfected with HIV type 1 and type 2

1 reference

12 December 2020

Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance

1 reference

12 December 2020

Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.00146-07

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

17576848

1 reference